Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a subsidiary of US pharma giant Merck & Co. 10 December 2019
Biotechnology
US pharma major Bristol-Myers Squibb presented data from multiple studies evaluating Reblozyl (luspatercept-aamt) in patients with anemia associated with multiple serious blood diseases at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. 10 December 2019
Biotechnology
The US business of South Korea’s Samyang Biopharm has entered into a research collaboration with Belgium’s Talix Therapeutics. 10 December 2019
Biotechnology
The US Department of Health and Human Services (HHS) is boosting capacity to produce recombinant influenza vaccine in the USA. 10 December 2019
Biotechnology
Cambridge, UK-based artificial intelligence specialist Healx has launched a collaboration with Germany’s Boehringer Ingelheim to identify indications related to rare neurological diseases. 9 December 2019
Biotechnology
US pharma major Bristol-Myers Squibb announced over the weekend that its Phase I study of lisocabtagene maraleucel (liso-cel) met its primary and secondary endpoints while demonstrating durable responses. 9 December 2019
Biotechnology
US pharma major AbbVie and non-profit Scripps Research today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis. 9 December 2019
Biotechnology
US biotech bluebird bio has presented new data from its Phase I/II HGB-206 study of its LentiGlobin gene therapy for sickle cell disease (SCD) at ASH. 9 December 2019
Biotechnology
Genomic medicine company Sangamo Therapeutics and its pharma partner Pfizer have announced updated follow-up results from the Phase I/II Alta study on the SB-525 gene therapy in patients with severe hemophilia A. 9 December 2019
Biotechnology
Newly-established FerGene has announced positive results from the pivotal Phase III clinical trial evaluating nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy, for the treatment of high-grade, Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). 9 December 2019
Biotechnology
At this year’s annual meeting of the American Society of Hematology (ASH), Johnson & Johnson has impressed with the first clinical data from its anti-BCMA CAR-T program, as rival candidates jostle for the lead in this area of innovation. 9 December 2019
Biotechnology
Sanofi has entered into a definitive agreement under which it will acquire all of the outstanding shares of US clinical-stage biotech Synthorx for $68 per share in cash. 9 December 2019
Biotechnology
The US Food and Drug Administration has granted Breakthrough Therapy designation for JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in previously-treated patients with multiple myeloma. 9 December 2019
Biotechnology
US biotech Cassava Sciences, previously known as Pain Therapeutics, was up 41% premarket on Friday on increased volume in reaction to new data from a Phase IIa clinical trial evaluating lead drug, PTI-125, in patients with mild-to-moderate Alzheimer's disease (AD). 9 December 2019
Biotechnology
Texas, USA-based XBiotech revealed on Saturday that it has entered into a definitive agreement with Janssen Biotech, part of US healthcare giant Johnson & Johnson, to sell its novel antibody, bermekimab, that neutralizes interleukin-1 alpha (IL-1⍺). IL-1⍺ promotes disease-causing inflammation in a wide range of medical conditions. 7 December 2019
Biotechnology
Sales of the multiple myeloma drug Darzalex (daratumumab) have hit $2.5 billion in a calendar year, which is good news not just for Janssen, the exclusive global license holder. 5 December 2019
Biotechnology
US immune-oncology drug developer RAPT Therapeutics and South Korea’s Hanmi Pharmaceutical have entered into a license and collaboration agreement for FLX475 in Asia, worth up to $118 million 5 December 2019
Biotechnology
The Australian biotech industry has voiced consternation at the government’s decision to move forward with a plan to cut R&D incentives in the country. 5 December 2019
Biotechnology
Idoesia has granted Japan’s Mochida Pharmaceutical an exclusive license for the supply, co-development and co-marketing of daridorexant, Idorsia’s dual orexin receptor antagonist (DORA), for insomnia and related disorders in Japan. 5 December 2019
Biotechnology
Privately-held US biotech Tetra Therapeutics has presented data showing that TNF-blocking agents reduce the risk of Alzheimer’s disease in patients with rheumatoid arthritis or psoriasis. 5 December 2019
All news
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze